Evaluation of serum uric levels in migraine.

OBJECTIVE: In our study, the aim was to identify the serum uric acid levels, a marker of oxidative stress, according to migraine subtypes (aura/without aura and episodic/chronic migraine). METHOD: The study included 300 migraine patients and 150 healthy controls for a total of 450 individuals. Migraine and subtypes were diagnosed according to International Classification of Headache Disorders-2013 criteria. Patients were evaluated during attendance at the neurology clinic. RESULTS: Our patient group was 77.0% female and disease duration was 9.2 ± 7.2 years. Our control group comprised 77.3% females. The age intervals in the patient and control groups were 36.4 ± 10.4 years and 36.0 ± 8.1 years. There was no statistically significant difference between our control and patient groups in terms of age and gender (p = .937 and p = .655). The serum UA, ferritin, and urea levels in our patient group were found to be significantly low compared to the healthy control group (p < .001). The serum UA levels in the migraine and control groups were 3.7 ± 0.7 and 4.6 ± 0.7 mg/dL, respectively (p < .001). There were no statistically significant differences observed between serum uric acid levels and other blood parameters between aura/without aura and episodic/chronic migraine subtypes (p > .05). CONCLUSION: Our study supports the hypothesis that the oxidative stress marker of serum uric acid levels may be associated with migraine diagnosis, concluding that serum uric acid levels were not significant for migraine subtypes.

The prevalence of sarcopenia and dynapenia according to stage among Alzheimer-type dementia patients.

BACKGROUND AND PURPOSE: In this study, the aim was to identify the prevalence of sarcopenia and dynapenia according to disease stage among Alzheimer-type dementia (AD) patients and collect data to suggest precautions related to reducing the disease load. METHODS: The study was completed with 127 patients separated into stages according to Clinical Dementia Rating Scale (CDR) criteria and 279 healthy volunteers aged 18-39 years and 70-80 years abiding by the exclusion criteria who agreed to participate in the research. Our prospective and cross-sectional study applied the CDR and mini mental test (MMSE) to patients with disorder in more than one cognitive area and possible AD diagnosis according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) diagnostic criteria. The patient and control groups had skeletal muscle mass index (SMMI), muscle strength and physical performance assessed with sarcopenia diagnosis according to European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: In our study, in parallel with the increase in disease stage of AD patients, the prevalence of sarcopenia (led by severe sarcopenia) and dynapenia was higher compared to a control group of similar age. CONCLUSION: In chronic, progressive diseases, like AD, identification of changes in parameters, like muscle mass and strength and reductions in physical performance in the early period, is important for identification and to take precautions in the initial stages considering the limitations of the preventive effects of treatment applied after diagnosis of AD.

Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson's disease.

AIM: In this study, the aim was to identify the incidence of sarcopenia and dynapenia according to disease stage among idiopathic Parkinson's disease (IPD) patients and collect data to illuminate precautions related to reducing the disease load. METHOD: The study was completed with 166 patients divided by stage according to modified Hoehn and Yahr (HYR) criteria and 249 healthy volunteers aged from 18 to 39 and 68 to 75 years met the inclusion criteria. In our prospective and cross-sectional study, patients with IPD according to "UK Brain Bank" diagnostic criteria had the Unified Parkinson's Disease Rating Scale (UPDRS) and HYR scales applied. The patient and control groups had skeletal muscle mass index (SMMI), muscle power, and physical performance assessed. Diagnosis of sarcopenia used the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: In our study, in parallel with the increase in disease stage among IPD patients, the incidence of sarcopenia (led by severe sarcopenia) and dynapenia was high compared to that among the control group of the same age. CONCLUSION: In the early stages of chronic progressive diseases like IPD, identification of sarcopenia and dynapenia is important considering the limitations of disease-preventive effects in treatments applied after diagnosis.

Assessment of the mental health of carers according to the stage of patients with diagnosis of Alzheimer-type dementia.

In this study, the aims were to assess the mental health state of carers for patients with Alzheimer-type dementia (AD) according to stage of disease and to collect data with the aim of determining precautions to reduce the load of the patient and disease on the carer. The study included 120 patients with stages determined, according to the clinical dementia rating scale (CDR), and 120 patient relatives above the age of 18 who cared for these patients every day, for the whole day or part of the day, and who accepted participation in the research. This prospective and cross-sectional study performed a detailed neurological examination of patients, and after completing the "personal information form" with the interviewer, each patient had CDR and mini-mental test (MMSE) applied to determine stage of dementia and physical state. Carers first completed the "personal information form" and then had the short symptom inventory (SSI) applied. According to the stage of patients, there were significant differences determined in the points for all sub-scales belonging to the SSI of carers. As the disease stage increased, all sub-scale points for the SSI increased. With the transition of disease stages from 0.5-1 to stage 2, from stage 2 to 3, and with the inverse reduction in MMT scores, the points obtained by carers on the SSI sub-scales increased. This data shows that with progressing disease stage, the load on the carer increases and mental health begins to dysfunction.

Electroclinical and prognostic characteristics of epilepsy patients with photosensitivity.

BACKGROUND AND PURPOSE: Epilepsy with photosensitivity (PSE) is one of the reflex epilepsy types with pathophysiology still unexplained. In our study we aimed to evaluate the clinical, electroencephalogram (EEG) and prognosis of patients with PSE diagnosis. METHODS: A total of 44 patients with PSE diagnosis according to international classification were included in this retrospective and cross-sectional study. The age, gender, syndrome, clinical and EEG characteristics of patients, and treatment response were investigated. RESULTS: The mean age was 22.09±6.49 years for 28 females and 16 males included in the study. Of patients, 17 had idiopathic photosensitive occipital lobe epilepsy (IPOLE), 11 had juvenile myoclonic epilepsy (JME), 11 had other PSE and 5 had juvenile absence epilepsy (JAE), with the most common visual trigger factors television and sunlight. In terms of seizure type, the most common was generalized tonic clonic seizure (GTCS), with myoclonus, absence and other seizure types observed. There was family history present in 17 patients and valproic acid was most commonly used for treatment. CONCLUSION: As noted in the literature, our data show that PSE has defined age group and clinical presentation, good prognosis but requires correct choice of medication for treatment. It is thought that good description of these epilepsy types will reduce misdiagnosis and mistreatment rates.

Assessment of mental health of carers according to patient stage of idiopathic Parkinson's disease.

BACKGROUND AND PURPOSE: In this study the aim was to collect data to assess the mental health of carers for patients with diagnosis of idiopathic Parkinson's disease (IPD) according to disease stage and to examine precautions to reduce the patient and disease load on carers. METHODS: The study included 144 patients with staging according to modified Hoehn and Yahr criteria and 144 patient relatives who provided care support for patients every day, for some or all of the day, and who were over the age of 18 years and accepted participation in the research. Our prospective and cross-sectional study performed detailed neurological examination of patients, and after completing the 'Personal Information Form' with the interviewer every patient, with idiopathic Parkinson's disease (IPD) according to 'UK Brain Bank' diagnostic criteria, had the 'Unified Parkinson's Disease Rating Scale (UPDRS)' and 'Modified Hoehn and Yahr scale (HYS)' applied. Carers first completed the 'Personal Information Form' and then had the 'Short Symptom Inventory (SSI)' applied. RESULTS: As the stage of disease increased, the points for all sub-scales of the Short Symptom Inventory increased. CONCLUSION: With the parallel increase in disease scores and UPDRS stage scores, the points obtained by carers on the SSI sub-scales increased. This data shows that with progressing disease stage, the load on the carer increases and mental health begins to be disrupted.

Assessment of Sleep Disturbances on Mental Health in Patients with Restless Legs Syndrome.

Background and Objective: In our study, we aimed to evaluate the sleep disturbances of patients diagnosed with restless legs syndrome (RLS) regarding their mental health according to the severity of the disease. Materials and Methods: The study included 166 patients diagnosed with RLS and 161 healthy controls in the same age interval as patients. Sleep disturbances of patients were defined with the "personal information form" (PIF) prepared by the researchers, while the mental health status of patients was defined with the "Brief Symptom Inventory" (BSI). Results: All RLS patients had an increase in BSI subscale points, with a positive correlation to disease severity, and subscale points were significantly higher than the control group (p < 0.05). Those with the "frequent waking" problem had higher BSI subscale points compared to those without the problem (p<0.01 or 0.001). Those with "waking with respiratory distress," "daytime sleepiness," "very early waking," and "sleep disorder" problems had statistically significantly high BSI subscale points for all subscales, apart from hostility, compared to those without these problems (p<0.01 or 0.001). Conclusion: It is considered that assessment of sleep disturbances causing disrupted quality of life and mood disorders is beneficial for the treatment of patients with RLS. Our study data appears to be related to the result that sleep disturbances and mental health disruptions might be associated with the disease severity among RLS patients.

A study of the relationship between serum uric acid levels and pain in patients with migraine.

Serum uric acid (SUA), the end product of purine metabolism acts as an antioxidant and is related to oxidative stress. It has been reported that SUA may be involved in the pathogenesis of neurodegenerative diseases including Alzheimer disease, Huntington disease, Parkinson disease, and multiple sclerosis. However, studies evaluating SUA levels in migraine are scarce. This study aimed to explore the relationship between pain characteristics and SUA levels in patients with migraine and compare SUA levels in migraine patients during a headache attack and headache-free period with those control groups. This prospective, cross-sectional study included 78 patients with migraine and 78 healthy subjects who were randomly selected from hospital personnel as the control group. Headache characteristics (duration of attack, pain intensity, and headache frequency) and sociodemographic features were recorded. The SUA level was measured once in the control group and twice in the migraine patients, during the migraine attack and headache-free periods. Although the SUA levels of the migraine group in the headache-free period were higher than those of the control group, the difference was not statistically significant. Gender was not significantly related to the change in SUA levels between the attack and headache-free period. When the correlation between age, duration of migraine, frequency, duration, and intensity of pain was evaluated; the difference between SUA levels in female migraine patients was weakly correlated with headache intensity, whereas male patients had a moderate correlation. ( P < .05; R > 0.250, and R > 0.516, respectively). The difference in SUA level in the migraine attack period compared to the headache-free period showing a positive correlation with pain intensity suggested that SUA may have a role in migraine due to its antioxidant role.

Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report.

BACKGROUND AND AIMS: Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD). METHODS: This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls. RESULTS: In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05). CONCLUSION: In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.

Evaluation of simple inflammatory blood parameters in patients with migraine.

AIM: This study aimed to identify the serum neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP)/albumin (CAR) ratios among patients with diagnosis of migraine according to migraine subtypes (attack/attack-free period, migraine with or without aura, episodic/chronic migraine, family history/no family history) and to collect data to investigate the role of inflammation and oxidative stress in etiology. METHOD: The study was completed with 235 patients with migraine diagnosis classified according to the International Classification of Headache Disorders-2013(ICHD) classification and 166 healthy controls. Patients with migraine were assessed during the attack by emergency medicine specialists in the emergency room and in attack-free periods in neurology clinics by neurology specialists. RESULTS: Of patients with migraine, 77.02% were female and 22.98% were male. The neutrophil, NLR, PLR, and MLR levels were higher than the control group (p < 0.05). The serum CRP, neutrophil, NLR, MLR, and CAR levels were higher, and albumin and lymphocyte levels were lower during migraine attack periods (p < 0.05). Migraines with aura were observed to have higher serum NLR levels compared to the aura-free patients (p < 0.05). Migraine patients with positive family history were found to have higher NLR levels compared to patients without a family history (p < 0.05). CONCLUSION: Although non-specific, serum NLR, MLR, PLR, and CAR levels may be potential biomarkers associated with migraine subtypes with different clinical features such as migraine attack period, migraine with aura, and patients with family history of migraine. Elevated inflammatory markers may indicate the severity of disease.

Prevalance of sarcopenia according to decade.

AIM: Our study aimed to identify Skeletal Muscle Mass Index (SMMI) cut-off values for sarcopenia diagnosis in our population and determine the prevalance of sarcopenia, and to collect data about reducing the disease load. METHOD: The study was completed with 515 volunteers divided into groups based on ages of 18-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years and 80 years and older. All groups had SMMI, muscle strenght physical performance assessed, with sarcopenia diagnosis made using the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: Together with advancing decades, there were significant reductions observed in SMMI, hand grip test (HGT) and 4-m walking test (4MWT) values. For females and males, the reduction in HGT and 4MWT values began after 50 years of age, while the reduction in SMMI began after 70 years for males and after 60 years for females. The prevalance of sarcopenia in the 40-49, 50-59, 60-69, 70-79 and 80 years plus age intervals were identified as 7%, 10.6%, 15.4%, 21.2% and 36.5%, respectively. CONCLUSION: Identification of sarcopenia prevalence in our population is important due to limitations of treatment administered after diagnosis is made.

Prevalence of sarcopenia in patients with geriatric depression diagnosis.

AIM: In this study, the aim was to identify the prevalence of sarcopenia among patients with geriatric depression (GD) diagnosis and to collect data to illuminate precautions to reduce disease load. METHOD: The study was completed with 116 patients (GD group) aged 65 years or older with possible or definite depression diagnosis according to the Geriatric Depression Scale (GDS) criteria and 301 volunteers aged from 18 to 39 years (control 1) and above 65 years (control 2). Our prospective and cross-sectional study applied the Hamilton Depression Rating Scale (HDRS) to control 1 group and the GDS and Mini Mental Test (MMSE) to control 2 and GD groups. All groups had skeletal muscle mass index (SMMI), muscle strength, and physical performance assessed with sarcopenia diagnosis according to the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: In our study, in parallel with the severity of disease in patients with GD diagnosis, the prevalence of sarcopenia (led by severe sarcopenia) was observed to be high compared to the control group. The prevalence of sarcopenia was 12.7%/24.2% among women and 13.8%/44.0% among men and 13.4%/32.8% in total in the control 2 and GD groups, respectively. There was a significant increase observed in the prevalence of sarcopenia, led by severe sarcopenia with a definite depression diagnosis. CONCLUSION: For GD patients, diagnosis of sarcopenia in the early stages and precautions like improving muscle functions with protein support in diet and resistance exercises will make it possible to contribute to improving clinical results of the disease.

A preliminary data: Evaluation of serum Galectin-3 levels in patients with Idiopathic Parkinson's Disease.

AIM: In our study, we aimed to collect data for the hypothesis that Galectin-3 might be used as a new prognostic and therapeutic biomarker in Idiopathic Parkinson's Disease (IPD). METHOD: In this prospective and cross-sectional study, the Unified Parkinson's Disease Rating Scale (UPDRS) and Modified Hoehn and Yahr (H&Y) scales were applied to each patient diagnosed as IPD according to the UK Brain Bank diagnostic criteria. The control group consisted of healthy individuals with the same age, gender, and body mass index characteristics as the patients meeting the exclusion criteria. RESULTS: A total of 111 cases were included in the study, 48 were IPD, and 63 were healthy controls. There were no statistically significant differences between the IPD and control groups in terms of demographic, anthropometric, and blood parameters (p > 0.05). Serum galectin-3 levels were significantly higher in IPD than the control group (p < 0.001). Serum galectin-3 levels, UPDRS scores, and duration of disease were significantly higher in patients with IPD in parallel with the progression of the disease (p < 0.001; 0.001; 0.009). No significant relationship was detected between the stage of the disease and other parameters (p < 0.05). CONCLUSION: Our study supports the hypothesis that serum galectin-3 level might be associated with IPD. Our data suggest that serum galectin-3 levels might be an accessible biomarker for the detection and prevention of chronic, progressive diseases such as IPH.

Serum C-reactive protein/albumin ratio and restless legs syndrome.

OBJECTIVES: Our study aimed to assess the variation in serum C-reactive protein/albumin ratio (CAR), a biomarker of peripheral inflammation and oxidative stress, in patients with restless legs syndrome (RLS). METHODS: The study included a total of 380 individuals including 197 with RLS diagnosis. RLS diagnosis was determined according to the "International Restless Legs Syndrome Study Group" questionnaire. Disease severity was assessed according to the "International Restless Legs Syndrome Study Group Severity Scale''. RESULTS: The mean age of patients with restless legs syndrome was 52.5 ± 12.7 years, while the mean age in the control group was 50.8 ± 11.2, with no statistically significant difference found (p = 0.156). The hemoglobin, iron and ferritin levels in the patient group were lower than in the control group (p < 0.001; p < 0.01; p < 0.001), with total iron binding capacity levels higher than the control group (p < 0.001). The mean ferritin in the RLS group (49.8 ± 51.2) was lower than the control group (76.9 ± 44.7). In patients, the c-reactive protein, albumin and c-reactive protein/albumin ratio were found to be 0.21 ± 0.18, 4.43 ± 0.31 and 0.07 ± 0.05, respectively. When compared with the control group, the patient group had high c-reactive protein (CRP), CAR and low albumin levels (p < 0.001). Among patients with "very severe" disease severity, ferritin levels were found to be lower than those with "moderate" disease severity. Additionally, patients with "very severe" disease had albumin levels which were significantly low compared to those with "mild" disease severity (p < 0.05). CONCLUSION: Our study supports the hypothesis that serum albumin level, ferritin, CRP, and CAR may be associated with restless legs syndrome.

Assessment of serum uric acid levels in patients with restless legs syndrome.

In our study, the aim was to collect data in relation to our hypothesis that oxidative stress is effective in the etiopathogenesis of restless legs syndrome (RLS) by assessing the serum uric acid levels, an important biomarker of oxidative stress, among RLS patients. The study included a total of 281 patients with restless legs syndrome diagnosis according to the "2012 Revised International Restless Legs Syndrome Study Group Diagnostic Criteria". Disease severity was assessed according to the "International Restless Legs Syndrome Study Group Severity Scale". The control group comprised 237 healthy individuals with the same age and gender features as the control group. The result showed no statistically significant difference in the mean age and gender between RLS and control group (p = 0.923; p = 0.433). The hemoglobin, ferritin, and uric acid levels of patients with RLS were found to be low (p < 0.001). Total iron-binding capacity level was higher in patients (p < 0.01; p < 0.05). In RLS patients, the serum uric acid level was not affected by disease severity (p > 0.05). Variables affecting uric acid level in RLS patients were determined to be age, disease duration, and hemoglobin level. The hypothesis that uric acid level, accepted as a biomarker of oxidative stress, is important in the pathogenesis of restless legs syndrome is supported by our study.